Francisco Chacón-Lozsán: Heparin-Induced Thrombocytopenia – When an Anticoagulant Triggers Thrombosis
Francisco Chacón-Lozsán, Fellow at World Extreme Medicine, Member of European Society of Intensive Care Medicine (ESICM) and American College of Cardiology, shared a post on X:
“Critical Physiology Series 94
Heparin-Induced Thrombocytopenia: When an Anticoagulant Triggers Thrombosis
A patient receiving heparin develops a 55% platelet-count reduction on day seven. There is no bleeding, but new pulmonary embolism appears. Think heparin-induced thrombocytopenia (HIT).
Pathophysiology
Immune HIT is not direct heparin toxicity. Heparin binds platelet factor 4 (PF4), forming complexes that can trigger pathogenic IgG antibodies.
PF4-heparin complexes bind IgG antibodies, which activate platelet FcγRIIa. Activated platelets release more PF4, amplifying the response. Simultaneously, monocytes, endothelium and coagulation pathways become activated.
Platelet activation leads to thrombin generation, which promotes thrombosis.
Platelets are consumed, producing thrombocytopenia, while thrombin generation creates a profoundly procoagulant environment.
This explains the paradox: Platelet count decreases while thrombosis risk increases. Both venous and arterial thromboses can occur.
Risk factors
HIT is more frequent with unfractionated heparin than LMWH. Risk is increased after major surgery, particularly cardiac and orthopedic procedures, and with prolonged exposure. Typical onset is 5 to 10 days after starting heparin. Rapid-onset HIT can occur with recent heparin exposure and circulating antibodies.
Diagnosis
Start with the 4Ts score:
- Thrombocytopenia
- Timing
- Thrombosis
- oTher causes
A low score (0-3) makes HIT unlikely.
Intermediate or high scores (4 or more) require investigation.
Request an anti-PF4 or heparin immunoassay. A positive immunoassay does not necessarily establish HIT because some antibodies are nonpathogenic.
Confirm platelet activation with a functional assay, preferably the serotonin-release assay (SRA) when available.
Importantly, HIT may occur even when the platelet count remains above 150 × 10⁹/L if the relative fall is substantial.
Monitoring
Follow:
- platelet-count trajectory
- new venous or arterial thrombosis
- limb perfusion
- hemoglobin or bleeding
- renal and hepatic function
- anticoagulant effect
Assess for occult DVT when indicated.
Management
For intermediate or high clinical suspicion:
Stop all heparin immediately, including flushes.
Do not wait for laboratory confirmation before initiating appropriate treatment.
Start a non-heparin anticoagulant.
In unstable ICU patients, argatroban or bivalirudin may be useful because of their short half-lives and titratability.
Fondaparinux or DOACs may be suitable in selected stable patients.
Avoid starting warfarin during acute thrombocytopenia because of limb-gangrene risk.
Routine platelet transfusion is generally avoided unless significant bleeding or another compelling indication exists.”
Title 1: American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia
Authors: Adam Cuker, Gowthami M. Arepally, Beng H. Chong, Douglas B. Cines, Andreas Greinacher, Yves Gruel, Lori A. Linkins, Stephen B. Rodner, Sixten Selleng, Theodore E. Warkentin, Ashleigh Wex, Reem A. Mustafa, Rebecca L. Morgan, Nancy Santesso
Read the Full Article on Blood Advances
Title 2: Heparin-induced thrombocytopenia
Authors: Gowthami M. Arepally
Read the Full Article on Blood
Title 3: Heparin-induced thrombocytopenia (and autoimmune heparin-induced thrombocytopenia): an illustrious review
Authors: Theodore E. Warkentin
Read the Full Article on RPTH Journal
Title 4: Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia
Authors: Vincent Hayes, Ian Johnston, Gowthami M. Arepally, Steven E. McKenzie, Douglas B. Cines, Lubica Rauova, Mortimer Poncz
Read the Full Article on Journal of Clinical Investigation
Other posts featuring Francisco Chacón-Lozsán on Hemostasis Today.
-
Oct 13, 2026, 21:04Aref Zribi: Isolated Tumor Thrombus and the Role of Prophylactic Anticoagulation
-
Oct 13, 2026, 21:01Alex Larson: Why Normal Bloodwork Does Not Always Tell the Whole Story
-
Oct 13, 2026, 20:58Juan Jauregui-Lozano: How Replication Stress Impairs Red Blood Cell Maturation
-
Oct 13, 2026, 20:55Caitlin Raymond: Understanding Platelet Refractoriness Before Ordering More Platelets
-
Oct 13, 2026, 20:54Sanja Seratlic: How Cow Feeding Systems Influence the Anti-Platelet Properties of Cheddar Cheese
-
Oct 13, 2026, 20:50Ruchika Goel: Cord Blood Red Blood Cells as a Physiologically Aligned Transfusion Strategy
-
Oct 13, 2026, 20:47Sophia Delicou: Strengthening Transfusion Safety Through Advanced Screening and Haemovigilance
-
Oct 13, 2026, 20:45Lydia Pecker: Alloimmunization and Transfusion Indications in Sickle Cell Disease Pregnancy
-
Oct 13, 2026, 15:51Merel Timmer: Hemophilia Twinning Partnership Strengthens Care and Quality of Life in Indonesia